Abpro Holdings, Inc.
abpro.coWhat Do They Do?
Develops antibody drug candidates for patients with cancer and eye diseases, using antibody discovery and engineering platforms.
10-K for FY2025, filed Apr 15, 2026Abpro Holdings, Inc. (together with its subsidiaries, the “Company”) is a biotechnology company dedicated to developing next-generation…View ↗
ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth…View ↗
DiversImmune® is our antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both…View ↗
MultiMab™ is our engineering platform that provides us with the flexibility to combine these antibody building blocks in different…View ↗
How Do They Make Money?
Partners pay for research and development services and may make upfront license payments and development or sales milestone payments; the company may also receive royalties when partners' product sales occur.
10-K for FY2025, filed Apr 15, 2026License and collaboration revenues - The Company’s license and collaboration revenues have been generated primarily through collaborative…View ↗
License of Intellectual Property - If a license to the Company’s intellectual property is determined to be distinct from the other…View ↗
Milestone Payments - At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical…View ↗
Royalties. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license…View ↗
We did not generate any material revenues during the years ended December 31, 2025 and 2024. Our research and development services revenue…View ↗
$183K
-
10-K for FY2024, filed Apr 15, 2025
$183K ↗
Who Are Their Customers?
Pharmaceutical and biotechnology partners work with the company to develop and commercialize antibody candidates under collaboration and license agreements.
10-K for FY2025, filed Apr 15, 2026ABP-102 is being developed and commercialized through a worldwide strategic partnership with Celltrion Inc. (“Celltrion”) (KRX:068270), a…View ↗
ABP 201 is being developed and commercialized through a territorial partnership with Abpro Bio, a subsidiary of Abpro Bio Co. Ltd…View ↗
ABP-201 is held through our majority-owned subsidiary AbMed Corporation, or AbMed. AstraZeneca (formerly MedImmune) owns a minority stake…View ↗
License and collaboration revenues - The Company’s license and collaboration revenues have been generated primarily through collaborative…View ↗
Do Revenues Turn Into Profits?
No. It lost $7.2M in FY2024.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$940KView ↗
- ▼ −68% (Loss)
- vs −$3M in Q2 FY2025
-
Sep 1, 2026
Chair Miles Suk resigned from his role as board chair
He remains a board member; the board plans to appoint a successor chair.
Sources
8-K, filed Sep 1, 2026
On August 25, 2026, Miles Suk provided notice of his voluntarily resignation from his position as Chairman of the Board of Directors of…View ↗
-
Aug 25, 2026
CEO Miles Suk resigned and an interim CEO was appointed
The board appointed M. Fatih Karatas as interim CEO.
Sources
8-K, filed Aug 25, 2026
On August 19, 2026, Miles Suk provided notice of his voluntary resignation from his position as the Chief Executive Officer to the Board of…View ↗
-
Jun 4, 2026
Nasdaq delisting was upheld
The company’s securities were set to be delisted after it failed to meet Nasdaq’s minimum equity standard.
Sources
8-K, filed Jun 4, 2026
On May 28, 2026, Abpro Holdings, Inc. (the “Company”) received written notification from the Nasdaq Listing and Hearing Review Council (the…View ↗
From blank-check company to antibody development
The older report described a blank-check company seeking a business combination, with a focus on mobility. The latest report describes a biotechnology company developing antibody therapeutics for cancer and eye diseases.
10-K for FY2022, filed Apr 3, 2023 10-K for FY2025, filed Apr 15, 2026
Who Do They Compete With?
Competes with Amgen, Bristol-Myers Squibb, Janux, J&J, Genentech, Vir Bio, Xencor, Allergan, Novartis International, and Regeneron Pharmaceuticals
10-K for FY2025, filed Apr 15, 2026Immune-based treatments for cancer, such as T-cell engager, CAR T and TCR therapies. Such as Amgen, Bristol-Myers Squibb Company, Janux…View ↗
Loading...
